Martina Rombaldova

Martina Rombaldova

Auto-generated profile, based on publicly available information

Martina Rombaldova

Department of Adipose Tissue Biology, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2016 in Diabetes
Verified
Journal Article
Open access
PDF file
OKOndrej Kuda
Ondrej Kuda
MBMarie Brezinova
Marie Brezinova
MRMartina Rombaldova
Martina Rombaldova
BSBarbora Slavikova
Barbora Slavikova
MPMartin Posta
Martin Posta
JKJr. Jan Kopecky
Jr. Jan Kopecky
White adipose tissue (WAT) is a complex organ with both metabolic and endocrine functions. Dysregulation of all of these functions of WAT, together with low-grade inflammation of the tissue in obese individuals, contributes to the development of insulin resistance and type 2 diabetes. n-3 polyunsaturated fatty acids (PUFAs) of marine origin play an important role in the resolution of inflammation and exert beneficial metabolic effects. Using experiments in mice and overweight/obese patients with type 2 diabetes, we elucidated the structures of novel members of fatty acid esters of hydroxy fatty acids—lipokines derived from docosahexaenoic acid (DHA) and linoleic acid, which were present in serum and WAT after n-3 PUFA supplementation. These compounds contained DHA esterified to 9- and 13-hydroxyoctadecadienoic acid (HLA) or 14-hydroxydocosahexaenoic acid (HDHA), termed 9-DHAHLA, 13-DHAHLA, and 14-DHAHDHA, and were synthesized by adipocytes at concentrations comparable to those of protectins and resolvins derived from DHA in WAT. 13-DHAHLA exerted anti-inflammatory and proresolving properties while reducing macrophage activation by lipopolysaccharides and enhancing the phagocytosis of zymosan particles. Our results document the existence of novel lipid mediators, which are involved in the beneficial anti-inflammatory effects attributed to n-3 PUFAs, in both mice and humans.

1 August 2017 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
MRMartina Rombaldova
Martina Rombaldova
PJPetra Janovska
Petra Janovska
JKJan Kopecky
Jan Kopecky
OKOndrej Kuda
Ondrej Kuda

21 May 2025 in European Heart Journal
Verified
Journal Article
Open access
TBTomas Baka
Tomas Baka
JMJarrod Moore
Jarrod Moore
FQFuzhong Qin
Fuzhong Qin
SYSalva Yurista
Salva Yurista
AZAifeng Zhang
Aifeng Zhang
ILIvan Luptak
Ivan Luptak
Background and Aims: Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disorder characterized by left ventricular hypertrophy (LVH), diastolic dysfunction, and impaired metabolic efficiency. This study investigates the therapeutic potential of the sodium–glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin (EMPA) in ameliorating these pathological features in a mouse model carrying the myosin R403Q mutation. Methods: Male mice harbouring the R403Q mutation were treated with EMPA for 16 weeks. Multi-nuclear magnetic resonance spectroscopy (31P, 13C, and 23Na MRS), echocardiography, transcriptomic, proteomic, and phosphoproteomic profiling were utilized to assess metabolic, structural, and functional changes. Results: Empagliflozin facilitated the coupling of glycolysis with glucose oxidation and normalized elevated intracellular sodium levels. Treatment resulted in a significant reduction in LVH and myocardial fibrosis as evidenced by echocardiography and histopathology. These structural improvements correlated with enhancements in mitochondrial adenosine triphosphate (ATP) synthesis, fatty acid oxidation, and branched-chain amino acid catabolism. Furthermore, EMPA improved left ventricular diastolic function and contractile reserve, underscored by improved ATP production and reduced energy cost of contraction. Notably, these benefits were linked to down-regulation of the mammalian target of rapamycin signalling pathway and normalization of myocardial substrate metabolic fluxes. Conclusions: Empagliflozin significantly mitigates structural and metabolic dysfunctions in a mouse model of HCM, underscoring its potential as a therapeutic agent for managing this condition. These findings suggest broader applicability of SGLT2i in cardiovascular diseases, including those due to myocardial-specific mutations, warranting further clinical investigation.

1 January 2016 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
OKOndrej Kuda
Ondrej Kuda
MRMartina Rombaldova
Martina Rombaldova
PJPetra Janovska
Petra Janovska
PFPavel Flachs
Pavel Flachs
JKJan Kopecky
Jan Kopecky

16 May 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
OHOlga Horakova
Olga Horakova
JHJana Hansikova
Jana Hansikova
Kristina BardovaKristina Bardova
Kristina Bardova
AGAlzbeta Gardlo
Alzbeta Gardlo
MRMartina Rombaldova
Martina Rombaldova
JKJan Kopecky
Jan Kopecky
Obesity is associated with insulin resistance and impaired glucose tolerance, which represent characteristic features of the metabolic syndrome. Development of obesity is also linked to changes in fatty acid and amino acid metabolism observed in animal models of obesity as well as in humans. The aim of this study was to explore whether plasma metabolome, namely the levels of various acylcarnitines and amino acids, could serve as a biomarker of propensity to obesity and impaired glucose metabolism. Taking advantage of a high phenotypic variation in diet-induced obesity in C57BL/6J mice, 12-week-old male and female mice (n = 155) were fed a high-fat diet (lipids ~32 wt%) for a period of 10 weeks, while body weight gain (BWG) and changes in insulin sensitivity (ΔHOMA-IR) were assessed. Plasma samples were collected before (week 4) and after (week 22) high-fat feeding. Both univariate and multivariate statistical analyses were then used to examine the relationships between plasma metabolome and selected phenotypes including BWG and ΔHOMA-IR. Partial least squares-discrimination analysis was able to distinguish between animals selected either for their low or high BWG (or ΔHOMA-IR) in male but not female mice. Among the metabolites that differentiated male mice with low and high BWG, and which also belonged to the major discriminating metabolites when analyzed in plasma collected before and after high-fat feeding, were amino acids Tyr and Orn, as well as acylcarnitines C16-DC and C18:1-OH. In general, the separation of groups selected for their low or high ΔHOMA-IR was less evident and the outcomes of a corresponding multivariate analysis were much weaker than in case of BWG. Thus, our results document that plasma acylcarnitines and amino acids could serve as a gender-specific complex biomarker of propensity to obesity, however with a limited predictive value in case of the associated impairment of insulin sensitivity.

25 October 2016 in Diabetes
Verified
Journal Article
Open access
PDF file
OKOndrej Kuda
Ondrej Kuda
MBMarie Brezinova
Marie Brezinova
MRMartina Rombaldova
Martina Rombaldova
BSBarbora Slavikova
Barbora Slavikova
MPMartin Pošta
Martin Pošta
TPTerezie Pelikanova
Terezie Pelikanova
In the article cited listed above, the grant number from the Czech Science Foundation was listed incorrectly and …